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Dear Editor,
Recently, our group published a paper in the Journal
validating, in cystic fibrosis (CF) patients, surrogate insulin
secretion indices against the gold standard method, the
Intravenous Glucose Tolerance Test (IVGTT) [1]. In this study,
we compared dynamic measures of insulin secretion during the
IVGTT and surrogate indices using data from an oral glucose
tolerance test (OGTT) in healthy control subjects as well as CF
patients with various glucose tolerances. We found that early
insulin secretion indices derived from the OGTT such as the one
proposed by Stumvoll et al. (1.283+1.829×Ins30 (pmol/L)
−138.7×Glyc30 (mmol/L)+3.772×Ins0 (pmol/L)) [2] or the
Insulin Secretion Rate (ISR, (Ins30− Ins0) (mU/L)/(Gly30−Gly0)
(mg/dL)) [3] can evaluate early insulin secretion in CF subjects.
However, when using these OGTT-derived indices in a large
database of 204 CF subjects, it appears that in 7% of cases,
essentially in patients with de novo diabetes, these formulas
provide negative values. In CF patients, because of significant
alteration in early insulin secretion [4], some patients
demonstrate in the first 30 min of the OGTT, a rapid glucose
rise without a concomitant significant insulin increase. In this
situation, these formulas will provide negative values which are
obviously without physiological significance and including
them into an analysis raises significant methodological
problems. To overpass this limitation, we reanalyzed previously
published data to determine if the Area Under the Curve (AUC)
obtained during time 0 to 30 min (AUC0–30) of the OGTT is
also a surrogate index of early insulin secretion in CF subjects
[1]. This measure correlates significantly with early insulin
secretion quantified with the IVGTT (AUC0–10) (r=0.59,
p=0.021 for healthy controls subjects, r=0.50, p=0.041 for
CF subjects). Therefore, this easily calculated value (AUC0–30)
obtained during the OGTT can be used as a proxy of insulin
secretion in CF patients. Its accuracy at various stages of the
disease should however be confirmed in futures studies.
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